IRVINE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine’s Transplant Institute and presented at the Rachmiel...Read more
Vancouver, Canada, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated...Read more
The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tablets The new unexpected PK profile allows for a once daily therapeutic...Read more
EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapyIn the Phase 3 EPCORE® FL-1 trial, EPKINLY + R2...Read more
REDEMPLO is the first and only FDA-approved medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often...Read more
EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting In the Phase 3 EPCORE® FL-1 trial, fixed duration EPKINLY + R2 demonstrated significantly superior progression-free survival...Read more
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Regeneron Pharmaceuticals | 21.52 3.06 | $725.83 |
| Jazz Pharmaceuticals | 11.91 7.00 | $182.00 |
| Olema Oncology | 11.69 137.21 | $20.21 |
| Thermo Fisher Scientific | 8.87 1.56 | $576.03 |
| Eli Lilly | 8.04 0.79 | $1,029.74 |
| Movano Health | 8.01 257.56 | $11.12 |
| Natera | 7.61 3.69 | $213.65 |
| Mettler-Toledo | 7.49 0.54 | $1,396.45 |
| Belite Bio | 6.28 5.37 | $123.19 |
| Spruce Biosciences | 6.16 5.66 | $115.00 |
| Ligand Pharmaceuticals | 5.70 2.83 | $207.05 |
| Madrigal Pharmaceuticals | 5.57 1.01 | $558.99 |
| McKesson | 5.52 0.65 | $860.75 |
| Insulet | 5.45 1.66 | $333.47 |
| Danaher | 5.07 2.30 | $225.51 |
| United Therapeutics | 4.67 0.99 | $476.59 |
| ICON | 4.53 2.89 | $161.02 |
| Medtronic | 4.52 4.69 | $100.80 |
| Company | Volume | Last Trade |
|---|---|---|
| Can-Fite BioPharma | 351,752,911 | $0.40 |
| Clearmind Medicine | 330,455,861 | $0.22 |
| Olema Oncology | 166,422,496 | $20.21 |
| Galmed Pharmaceuticals | 131,738,250 | $1.10 |
| Applied Therapeutics | 117,823,511 | $0.30 |
| Inotiv | 65,403,261 | $0.85 |
| Pfizer | 64,545,478 | $25.45 |
| Recursion | 49,637,270 | $4.17 |
| Invivyd | 47,841,434 | $2.53 |
| Incannex Healthcare | 35,562,845 | $0.34 |
| Iovance Biotherapeutics | 33,067,574 | $2.44 |
| Esperion | 28,027,816 | $2.83 |
| Merck | 26,893,188 | $96.43 |
| Autonomix Medical | 26,299,800 | $0.94 |
| Medtronic | 21,416,458 | $100.80 |
| InMed Pharmaceuticals | 19,599,098 | $1.46 |
| Arvinas | 18,536,622 | $12.99 |
| Neuronetics | 17,396,507 | $1.50 |
| ImmunityBio | 17,287,654 | $2.10 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
